Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ’s Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback